

Landmark North America aged care deployment with Sabra targeting 20k beds

- Sabra, a \$5b Nasdaq-listed healthcare REIT, to fund PainChek across its 329 skilled nursing, long-term care & senior housing facilities in the US & Canada
- Key milestone for PainChek’s rollout across North America after receipt of FDA approval in 2025
- Pricing agreement of \$55-75 USD per bed per annum
- Sabra to introduce PainChek to all current & future operators in its network
- This agreement model has significant potential to be replicated across other REITs and institutional asset owners in North America

Sydney, Australia, 14 April 2026 – PainChek Ltd (ASX: PCK), developer of the world’s first AI-powered pain assessment and monitoring application, is pleased to announce it has entered into a Master Services Agreement with Sabra Health Care REIT, Inc. (Nasdaq: SBRA) (“Sabra”), a leading owner of healthcare real estate assets across North America, that will see PainChek funded for as many as 20,000 beds across its 329 skilled nursing, long-term care and senior housing facilities.

The agreement represents a strategic commercial milestone for PainChek, establishing a repeatable, capital-light go-to-market mechanism that will facilitate broad PainChek adoption across Sabra-owned senior housing communities.

Under the agreement, Sabra will fund the cost of PainChek’s solution on behalf of its operating partners, significantly reducing barriers to adoption at the operator level. The pricing agreement ranges from \$55-\$75 USD per bed per annum, with the lower end pricing only available for clients with long term agreements (2-3 years) or who participate in a collaborative research or outcomes publication project with PainChek. This is a perpetual agreement with the option for either party to terminate with 90 days’ notice after the initial 12-month period.

Sabra is obligated to introduce PainChek to all current and future operators within its portfolio. The owner-level endorsement and financial support materially increase the likelihood of operator uptake, streamlining sales cycles and deployment and enabling PainChek to pursue broad portfolio penetration without proportional increases in sales and marketing investment.

Sabra has a market capitalisation of approximately \$5 billion, placing it among the larger specialised healthcare REITs in North America, having more than 36,000 beds or units in the US and Canada.

PainChek believes this owner-led pricing and distribution model is highly replicable across other REITs and institutional asset owners, supporting the Company’s strategy to scale efficiently in the North American market.

Philip Daffas, CEO of PainChek, commented:

“We are delighted with this major commercial agreement with Sabra Health Care. This agreement facilitates the accelerated uptake of PainChek across Sabra’s network of long-term care and senior housing facilities. The PainChek roll out will be in stages, and we are currently finalizing local agreements based on the agreed Sabra pricing with an initial five operators. This is expected to be followed by an additional ten operators in the queue.

“This model is also a blueprint for PainChek in the US and transferrable to other large, US-based real estate investment trusts who own large numbers of long-term care and senior living facilities.”

This announcement has been approved for release by the Board.

For more information:

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About Sabra Health Care

Sabra Health Care REIT, Inc. is a U.S.-based healthcare real estate investment trust (REIT) that owns and invests in properties serving the healthcare and senior-care sector. Founded in 2010 and headquartered in Tustin, California, Sabra’s portfolio includes long-term care (skilled nursing) facilities, senior housing communities, and behavioural health and specialty hospitals across the United States and Canada.

<https://sabrahealth.com/>

About PainChek

[PainChek](#)® is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom.

PainChek® has contracts with over 2,000 aged care facilities, with more than 18,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centers have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>